- Home
- CNR vs GPCR Comparison
CNR vs GPCR Comparison
Compare CNR & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | CNR | GPCR |
|---|---|---|
| Founded | 1864 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.8B |
| IPO Year | 2017 | 2023 |
Fundamental Metrics
Financial Performance| Metric | CNR | GPCR |
|---|---|---|
| Price | $87.73 | $21.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 16 |
| Target Price | ★ $109.50 | $105.78 |
| AVG Volume (30 Days) | 410.9K | ★ 1.2M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.46% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.91 | N/A |
| Revenue | ★ $2,236,311,000.00 | N/A |
| Revenue This Year | $8.46 | N/A |
| Revenue Next Year | $1.87 | N/A |
| P/E Ratio | $29.99 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $74.75 | $20.73 |
| 52 Week High | $114.80 | $94.90 |
Technical Indicators
Market Signals| Indicator | CNR | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 42.21 | 22.84 |
| Support Level | $85.85 | N/A |
| Resistance Level | $91.42 | $57.15 |
| Average True Range (ATR) | 2.77 | 1.43 |
| MACD | 0.02 | 0.17 |
| Stochastic Oscillator | 20.50 | 14.61 |
Price Performance
Historical ComparisonAbout CNR Core Natural Resources Inc.
Core Natural Resources Inc is a producer and exporter of metallurgical and thermal coal. The company owns and operates longwall mining operations in the nation and export terminals on the Eastern seaboard. The activities of the company involves mining of thermal coal, power generation, and other related activities.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.